we believe pharmaceutical R&D spend will continue to grow and global providers like ICON are well positioned to expand and gain share over time, returning to double-digit EPS growth. With the stock ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

ICON Flexible Bond Fund earns an Above Average ... Over the trailing eight-year period, this share class underperformed the category's average return by an annualized 22 basis points.

Fintel reports that on April 10, 2025, Barclays downgraded their outlook for ICON Public Limited (NasdaqGS:ICLR) from ...

IQVIA (IQV) stock, ICON (ICLR) stock, and Fortrea (FTRE) stock were downgraded at Barclays, citing impact from potential pharma tariffs. Read more here.

under the existing trading symbol “ICON.” The new CUSIP number for the Common Shares following the Reverse Stock Split will be Y4001C 206. When the Reverse Stock Split becomes effective ...